"We started this year with one globally successful product, Nexavar, approved for the treatment of 2 types of cancer and a bold vision for building a leading oncology company with multiple therapies to help even more patients with cancer.
Specifically, our objective was to have, by the end of this year, 2 newly approved oncology therapies, bringing the total number of medicines in the Onyx portfolio to 3 across an array of solid and liquid tumors. We knew this would be an ambitious goal, but I'm very pleased and very proud to say that we have achieved this important milestone. And with this achievement, Onyx has truly been transformed, both as a company and as a business. We're focused on growing our top line and continuing our evolution as a leading biopharmaceutical company
Within our proteasome inhibitor franchise, we're beginning to unlock the significant potential we see for Kyprolis globally. we remain committed to investing both strategically and prudently in a comprehensive registration program for Kyprolis across multiple lines of myeloma treatment.
We continue to make good progress with our oral proteasome inhibitor oprozomib, as we are now advancing a new formulation for this therapy in the clinic. Ultimately, both of these programs are driven by our intense interest in transforming myeloma into a disease that is chronic and no longer uniformly fatal.
Turning to our kinase inhibitor franchise. Just over a month ago, Bayer received U.S. FDA approval of Stivarga for patients with previously treated metastatic colorectal cancer. The U.S.-based Onyx and Bayer teams began executing launch plans immediately, leveraging and expanding our kinase inhibitor sales force to co-promote both Nexavar and Stivarga.
In parallel, Bayer continues to make significant regulatory progress with global filings for both colorectal cancer and GIST. As a reminder, Onyx will receive a 20% royalty on net sales of Stivarga globally without any development or commercialization investment required.
As you know, the cornerstone of our kinase inhibitor franchise continues to be Nexavar, a therapy reaching patients globally in over 100 countries. Nexavar contributes important cash flow for our business as a treatment for both unresectable liver cancer where it maintains its unique leadership position despite multiple competitive attempts, and for kidney cancer where it remains an important treatment option.